FindTrial
Sign In

Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

Effectiveness and Safety of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer: A Multi-center Real-world Retrospective Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06356519
Enrollment
150
Registered
2024-04-10
Start date
2024-03-01
Completion date
2025-04-01
Last updated
2024-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Sacituzumab Govitecan, breast cancer

Brief summary

The aim of this trial is to explore the real-world effectiveness and poteintial predictors of Sacituzumab Govitecan in Chinese metastatic breast cancer patients.

Interventions

DRUGSacituzumab Govitecan

Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w

Sponsors

Fudan University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Patients aged over 18 years old. 2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 3. Plan to receive or has received Sacituzumab Govitecan monotherapy 4. Available medical history.

Exclusion criteria

1. Incomplete medical history. 2. Pregnancy or breast-breeding

Design outcomes

Primary

MeasureTime frameDescription
PFS6 weeksProgression free survival

Secondary

MeasureTime frameDescription
OS6 weeksOverall Survival
Number of participants with treatment-related adverse events as assessed by CTCAE v5.06 weeksSafety
ORR6 weeksOverall Response Rate

Countries

China

Contacts

Primary ContactBiyun Wang, Professor
pro_wangbiyun@163.com+8613701748410

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026